Report
Franc Gregori ...
  • Lala Gregorek
  • Philippa Gardner

Trinity Delta Lighthouse: ANGLE

Trinity Delta view: All the building blocks remain in place at ANGLE to deliver sustainable long-term growth from both Products and Services. However, in the near-term, resources will be appropriately focused on maximising the Pharma Services opportunity to capitalise on the recent momentum in this business. As and when conditions improve in the Products business, ANGLE is prepared and has the elements in place to re-invigorate this revenue stream. Whilst the slowdown in Products will impact near-term revenues, the Pharma Services focused strategy, particularly on large pharma, is an attractive mid-term opportunity. The Pharma Services sales cycle can be protracted for new customers; however, the prospect of broader relationships with existing clients could be swifter. Our valuation and forecasts remain suspended; for reference our last published ANGLE valuation was £174m, or 67p/share. .
Underlying
ANGLE PLC

ANGLE is a holding company. Through its subsidiares, Co. operates as a medical diagnostic company focusing on the development of products in the fields of cancer diagnostics and foetal health. Co. develops products for use in rare cell diagnostics that enable early identification of an individual's condition for the prevention, treatment, and monitoring of disease. Co.'s principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy (non-invasive cancer diagnostics).

Provider
Trinity Delta
Trinity Delta

We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.

The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.

We also firmly believe that by putting our clients first, we create long term value for all stakeholders.

Analysts
Franc Gregori

Lala Gregorek

Philippa Gardner

Other Reports on these Companies
Other Reports from Trinity Delta

ResearchPool Subscriptions

Get the most out of your insights

Get in touch